Glioma cells migration stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA) are attenuated by adding Kaempferol (KPF-BBR) and biomodified Kaempferol (KPF-ABR). (A) A decreased Matrix Metalloproteinase 9 (MMP-9) mRNA expression level is observed when NG-97 [0.33 AUs (SD: 0.28) vs. 1.02 AUs (SD: 0.24), p-value = 0.03; 0.54 AUs (SD: 0.01) vs. 1.02 AUs (SD: 0.24); p-value = 0.03] and U251 cells [0.81 AUs (SD: 0.05) vs. 1.03 AUs (SD: 0.33), p-value = 0.30; 0.36 AUs (SD: 0.05) vs. 1.03 AUs (SD: 0.33); p-value = 0.02] are exposed to KPF-BBR or KPF-ABR, respectively, compared with the untreated control cells. (B) MMP-9 expression level is inhibited by KPF-BBR [0.60 AUs (SD: 0.32) vs. 1.84 AUs (SD: 0.66), p-value = 0.04] and by KPF-ABR [0.57 AUs (SD: 0.05) vs. 1.84 AUs (SD: 0.66); p-value = 0.03] in NG-97 cells stimulated by TPA and compared with the TPA-treated cells. In addition, the MMP-9 expression level is also abrogated by KPF-BBR [0.82 AUs (SD: 0.06) vs. 4.50 AUs (SD: 0.57), p-value = 0.0004] and by KPF-ABR [1.43 AUs (SD: 0.28) vs. 4.50 AUs (SD: 0.57); p-value = 0.001] in the U251 cell line stimulated by TPA and compared with the TPA-treated cells. These results suggest that both KPFs have an anti-migratory effect on gliomas cells. The data presented are the mean ± standard deviation (SD) of the experiments performed in triplicate. AUs: arbitrary units.